Experimental Design: Oral erlotinib was taken daily starting with a 14-day run-in and continued until RT was completed. Low-dose daily cisplatin, 6 mg/m2 IV was given concurrently with standard fractionation RT to a total dose of 66-70 Gy. Dose escalation followed a modified Fibonacci dose escalation design.
Author Manuscript Published OnlineFirst on January 23, 2012; DOI: 10.1158/1078-0432.CCR- platinum-based concurrent chemoradiotherapy (CCR) or surgery plus adjuvant radiotherapy (with or without chemotherapy), the overall survival of patients with local-regionally advanced (stages III-IV, M0) oral squamous cell carcinoma (HNC) remains poor. In particular, patients with human papillomavirus (HPV) negative cancers have a 2-year overall survival of less than 60% (1).
Intergroup Trial 9111 has established high-dose cisplatin concurrently administered with radiation therapy as the standard of care for organ preservation for advanced laryngeal cancer (2) . This combination has also been applied as a non-surgical, curative approach to locally advanced cancers arising from other anatomic sites (3) (4) (5) . A meta-analysis found that cisplatin-based concurrent chemoradiotherapy led to the greatest improvement in overall survival 4 . However the optimal dose and schedule of cisplatin has not been determined The Epidermal Growth Factor Receptor (EGFR) and its ligands, EGF and TGFalpha, play important roles in cell proliferation, motility, adhesion, invasion, survival and angiogenesis (8) .
Abnormalities of EGFR signal transduction are common in squamous cell carcinomas of the head and neck. Overexpression of EGFR has been demonstrated in the majority (80-100%), and may be related to advanced T stage and presence of nodal disease. EGFR overexpression has also been shown to be a predictor of survival (9) (10) .
Treatment of tumor cells in vitro with anti-EGFR antibody induces arrest of cells in G 1 with an increase in the cyclin-dependent kinase inhibitor p27kip1 and a decrease in retinoblastoma protein (Rb) phosphorylation (11) . Moreover, synergy exists between EGFR inhibition, radiation and chemotherapy. Although not completely understood, these observations may be related to inhibition of multiple growth-promoting signals such as the anti-apoptotic effect of EGFR and EGF-related growth. Additionally, inhibition of cross-talk between the EGFRsignaling and other growth-promoting pathways may heighten sensitivity to the cytotoxic effects of traditional chemotherapeutic agents (12-15).
Erlotinib is an orally active potent, selective inhibitor of the EGFR tyrosine kinase.
In a phase II trial, single agent erlotinib demonstrated a low response rate (~4%) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). In combination with cisplatin, a response rate of 21% was observed in a phase I/II trial in a similar patient population, and rates of grade 3
Research. and 4 toxicity were minimal. Although the safety and tolerability of combination therapy with erlotinib, cisplatin and radiation has already been investigated in other malignancies this regimen may not be as well tolerated for head and neck primary tumors (16) (17) (18) .
This trial was designed to evaluate whether the addition of erlotinib to combination chemoradiation (CCR) would produce acceptable toxicities and preliminary evidence of efficacy in patients with locally advanced oral cavity or oropharyngeal cancer. Moreover, the trial aimed to determine the maximum tolerated dose of the combination of daily oral erlotinib in combination with cisplatin and radiation therapy. The pharmacokinetic sampling scheme employed in this trial was designed to measure the erlotinib steady-state concentrations achieved and to ensure that adequate concentrations are sustained during chronic oral administration of erlotinib alone and in combination with standard fractionation external beam radiation therapy with or without low dose daily cisplatin chemotherapy. Finally, the trial evaluated whether a two week window period of erlotinib alone could elicit evidence of a metabolic response on serial 18 F-FDG PET imaging.
Patients and Methods
Research. 
Study Design and Dose Escalation
The principal objective of the study was to determine the Maximally Tolerated The MTD was defined as the dose of erlotinib in combination with cisplatin and radiation therapy in which < 2 of 6 patients experiences a DLT.
After the recommended Phase II dose (MTD) was defined, 6 additional patients were enrolled at that dose level.
Dose modifications
Dose adjustments were made for Grade 3 or 4 toxicity. The offending agents could be held for up to 14 days until toxicity resolved to grade 1 or less.
Radiation therapy was allowed to continue if erlotinib, the platinum or both were held. If erlotinib was held, RT and platinum could continue at the discretion of the investigator. If platinum held, erlotinib and RT could continue at the discretion of the investigator. If RT held, erlotinib could continue but platinum was held. If the agent causing the toxicity was unknown, then all 3 were held until toxicity resolved to grade 1 or less. The erlotinib was then dose reduced per guidelines.
Patients were removed from study if toxicity did not resolve within 14 days or if greater than two dose adjustments were required.
Response evaluation and follow-up
Although response was not the primary endpoint of this trial, patients who completed chemoradiotherapy were evaluable for response. Patients with progressive disease were evaluable if they received at least 30 days of combined modality therapy. Response and progression were evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) (19) . A modified radical neck dissection was planned for patients with initial presentation that demonstrated N2a or greater neck involvement at presentation. A biopsy at the primary site was performed if recurrence was suspected.
Pharmacokinetic sampling and analysis
Whole blood samples were collected on days 1 and 2 and then weekly for 10 weeks before drug administration. Plasma was separated by centrifugation and frozen at -70˚C until analysis. Plasma concentrations of erlotinib 1(range 0 to 10,000 ng/mL ) and OSI-420 (1 to 1000 ng/mL), the major active metabolite,
were measured using a validated reversed-phase high-performance liquid chromatography assay with tandem mass spectrometry detection (21) . Quality control samples were assayed with each analytic run and were within 15% of the nominal concentration.
Erlotinib pretreatment trough concentration (C min ) was evaluable if the sample was collected 18 to 30 hours after drug dose and the patient was compliant (e.g., 80% of drug administration during sampling interval). C min at steady state (C ss,min ) was determined as the average of the pretreatment erlotinib and OSI-420 concentrations on days 8 and 15 (when administered alone) and on days 22, 29, 36, 43, 207, 57, and 64 (when administered in combination with radiation with or without cisplatin). The C ss,min ratio of metabolite to erlotinib was calculated.
Statistical Analysis
Toxicity, responses, and pharmacokinetics were summarized using descriptive 
Results

Patients
Twenty-two patients were enrolled and 18 patients received therapy on protocol. characteristics of the 18 patients who received therapy are shown in Table 2 .
Median age was 56 (range 42-66), and the majority were Caucasian males.
Three patients were withdrawn from protocol therapy. One patient experienced grade 3 pneumonitis (n=1). This patient also had a possible pulmonary infection.
The relationship to erlotinib was deemed possible and patient was removed from study before completing CCR. Two other patients were withdrawn from protocol without experiencing DLT. One patient was, diagnosed with Fanconi's anemia (n=1), and another had a diagnosis of metastatic disease by PET on day 14.
These three patients were subsequently replaced on study.
Safety Experience: Dose Escalation
One of three patients at dose level 1 (50 mg erlotinib) experienced grade 3 neutropenia and fever and therefore the first cohort was expanded to 6. No dose limiting toxicity was noted in the 3 additional patients. A total of 5 patients were enrolled on dose level 2, erlotinib 100 mg/day. Two were removed from protocol therapy, one due to grade 3 pneumonitis with an attribution of possibly related to erlotinib. One was removed due to a diagnosis of Fanconi's anemia. Three patients. In the expanded cohort, 1 patient experienced grade 3 neutropenia, 1 experienced grade 3 anorexia. However, these toxicities were not considered dose limiting. Grade 3/ 4 toxicities attributed to the addition of erlotinib to CCR include lymphopenia, diarrhea, rash and pneumonitis.
One patient in dose level 1 required an 8 day treatment break for grade 4 mucositis. Otherwise, no treatment breaks greater than 3 days occurred. The details of the RT from the LSU site are not known due to destruction of patient records in Hurricane Katrina. See Table 3 for Grade 3/ 4 toxicities.
Response Evaluation
A total of 18 patients were evaluable for response assessment at the completion of combined modality treatment. The average time to clinical response determination was 119 days (range 64-194 days). Best overall response is summarized in Table 4 .
Thus, overall response rate derived from tumor measurements based on imaging studies was 83% for all dose levels combined. Response evaluation took place at an average of 83 days post CCR (range 64-194 days).
Pharmacokinetic Evaluation
Research. Plasma pharmacokinetic studies were performed on specimens from 16 patients.
One patient was removed from evaluation due to non-compliance. Trough values were obtained 65% of the time. There was no difference in erlotinib C ss,min (p=0.30), OSI-420 C ss,min (p=0.20), or the C ss,min ratio of OSI-410:erlotinib (p=0.30) when erlotinib was administered alone or combination with radiation and cisplatin (see Table 5 ). Additionally, there was no difference in dose-normalized C ss,min as a function of dose level for erlotinib (p=0.14) or OSI-410 (p=0.23)or in the ratio of OSI-410:erlotinib (p=0.07) with increasing ratios with increasing erlotinib dose.
Pharmacokinetic-pharmacodynamic Correlations
No correlation was observed between clinical responses (Table 1) Table 6 , stratified by erlotinib dose level. Scans for two patients at dose level 2 on day 120 were not performed per patient request.
There was evidence for metabolic response to single agent erlotinib. Per PERCIST criteria, the overall metabolic response rate at day 14 was 38.8% at day 14 appeared greater at the second and third dose levels, but differences were non-significant (median 6.8 vs. 28.7 vs. 21.8, k-wallis p=0.41, dose levels 1, 2, and 3, respectively). All but two evaluable patients had a metabolic response to treatment at the day 120 evaluation, with the majority (7 of 10) of the patients at the highest dose level having no SUV uptake over background at this time point.
Discussion
Based on this Phase I investigation, the combination of standard fractionation RT, low dose daily cisplatin and daily erlotinib is well tolerated. MTD was not reached. The recommended phase II dose of erlotinib is 150 mg per day in combination with cisplatin and radiation therapy, the highest dose of erlotinib evaluated in this study. Importantly, while 1 patient demonstrated Grade 3 rash, overall skin toxicity (including radiation dermatitis) and mucositis were consistent with historical controls that used concurrent RT and platinum. Additionally, only two patients had treatment breaks and one of these breaks was due to non-study related issues again demonstrating the tolerability of the regimen. Only 1 patient had a break due to mucositis. Pill diaries and pharmacokinetic assessment demonstrated good compliance with the daily dosing of the erlotinib. Our pharmacokinetic data demonstrated that cisplatin and RT did not affect steady state levels of erlotinib and is consistent with previously published data (18) . 
expected for RT alone) and a response rate of 70%. In our study, EGFR inhibition did not increase the rate of grade 3-4 mucositis over CCR alone and compares favorably to others studies of EGFR inhibition plus CCR (25) 
Schema:
67.8 ± 53.7
0.09 ± 0.03 
